ADC’s Phase II Data May Position ‘Lonca’ To Compete With Roche’s Polivy

 
• By Joseph Haas

The antibody-drug conjugate yields a 48% overall and 24% complete response rate in a pivotal Phase II DLBCL study. The Swiss biotech hopes to compete with Polivy and is studying combo therapy with Imbruvica.

Lymphoma cancer cell - 3d rendering
ADC Therapeutics thinks Lonca has broad potential across lymphoma settings

More from Clinical Trials

More from R&D